JP2010510215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510215A5 JP2010510215A5 JP2009537199A JP2009537199A JP2010510215A5 JP 2010510215 A5 JP2010510215 A5 JP 2010510215A5 JP 2009537199 A JP2009537199 A JP 2009537199A JP 2009537199 A JP2009537199 A JP 2009537199A JP 2010510215 A5 JP2010510215 A5 JP 2010510215A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- aliphatic
- fluoro
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 41
- 125000001931 aliphatic group Chemical group 0.000 claims description 24
- -1 N-methylpyrrolidinyl Chemical group 0.000 claims description 13
- 102000003989 Aurora kinases Human genes 0.000 claims description 11
- 108090000433 Aurora kinases Proteins 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 2
- 102000004000 Aurora Kinase A Human genes 0.000 claims description 2
- 108090000461 Aurora Kinase A Proteins 0.000 claims description 2
- 101150065749 Churc1 gene Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100038239 Protein Churchill Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- SRFVRJILPIASPG-UHFFFAOYSA-N 4-[[7-(2-fluoro-6-methoxyphenyl)-9-(1-methylpyrrol-2-yl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C=2N(C=CC=2)C)=C1 SRFVRJILPIASPG-UHFFFAOYSA-N 0.000 description 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 description 1
- NRJOLMQQQLDIPP-UHFFFAOYSA-N 4-[[9-ethynyl-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)C#C)=C1 NRJOLMQQQLDIPP-UHFFFAOYSA-N 0.000 description 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
- AIUYVPGHBMKGAC-UHFFFAOYSA-M sodium;4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoate Chemical compound [Na+].C1=C(C([O-])=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 AIUYVPGHBMKGAC-UHFFFAOYSA-M 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85934006P | 2006-11-16 | 2006-11-16 | |
| US60/859,340 | 2006-11-16 | ||
| PCT/US2007/023948 WO2008063525A1 (en) | 2006-11-16 | 2007-11-14 | Compounds for inhibiting mitotic progression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011187930A Division JP5452811B2 (ja) | 2006-11-16 | 2011-08-30 | 有糸分裂進行を阻害するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510215A JP2010510215A (ja) | 2010-04-02 |
| JP2010510215A5 true JP2010510215A5 (enExample) | 2011-10-20 |
| JP5102839B2 JP5102839B2 (ja) | 2012-12-19 |
Family
ID=39315133
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537199A Active JP5102839B2 (ja) | 2006-11-16 | 2007-11-14 | 有糸分裂進行を阻害するための化合物 |
| JP2011187930A Active JP5452811B2 (ja) | 2006-11-16 | 2011-08-30 | 有糸分裂進行を阻害するための化合物 |
| JP2013236439A Pending JP2014055166A (ja) | 2006-11-16 | 2013-11-15 | 有糸分裂進行を阻害するための化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011187930A Active JP5452811B2 (ja) | 2006-11-16 | 2011-08-30 | 有糸分裂進行を阻害するための化合物 |
| JP2013236439A Pending JP2014055166A (ja) | 2006-11-16 | 2013-11-15 | 有糸分裂進行を阻害するための化合物 |
Country Status (34)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE381566T1 (de) | 2004-05-14 | 2008-01-15 | Millennium Pharm Inc | Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| TW201026703A (en) * | 2008-12-05 | 2010-07-16 | Millennium Pharm Inc | Thiolactams and uses thereof |
| ES2468391T3 (es) * | 2008-12-22 | 2014-06-16 | Millennium Pharmaceuticals, Inc. | Combinación de inhibidores de cinasas Aurora y anticuerpos anti-CD20 |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| JP2013520424A (ja) * | 2010-02-19 | 2013-06-06 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
| US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
| ES2526671T3 (es) * | 2010-06-22 | 2015-01-14 | Glaxosmithkline Llc | Compuestos de benzotriazoldiazepina inhibidores de bromodominios |
| AR086656A1 (es) * | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN103772391A (zh) * | 2012-10-23 | 2014-05-07 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| WO2016106357A1 (en) * | 2014-12-23 | 2016-06-30 | Millennnium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| WO2017015316A1 (en) | 2015-07-21 | 2017-01-26 | Millennium Pharmaceuticals, Inc. | Administration of aurora kinase inhibitor and chemotherapeutic agents |
| JP6955485B2 (ja) | 2015-09-09 | 2021-10-27 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| EP3347350A1 (en) | 2015-09-09 | 2018-07-18 | Icahn School of Medicine at Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
| JP6591036B2 (ja) | 2016-02-26 | 2019-10-16 | 公益財団法人がん研究会 | Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系 |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| JP6188986B1 (ja) * | 2017-03-23 | 2017-08-30 | 株式会社ノエビア | 時計遺伝子発現量調整剤及びエラスチン産生促進剤 |
| US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
| WO2020049208A1 (es) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida |
| WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
| EP4504710A1 (en) | 2022-04-07 | 2025-02-12 | Eli Lilly and Company | Process for making a kras g12c inhibitor |
| EP4504209A1 (en) | 2022-04-08 | 2025-02-12 | Eli Lilly and Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
| EP4547251A1 (en) | 2022-06-30 | 2025-05-07 | Eli Lilly and Company | Kras g12c inhibitor for treating cancer |
| WO2025075211A1 (en) | 2023-10-03 | 2025-04-10 | Takeda Pharmaceutical Company Limited | Alisertib and paclitaxel for treating small cell lung cancer |
| WO2025245045A1 (en) | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| FR2450833A1 (fr) | 1979-02-07 | 1980-10-03 | Hoffmann La Roche | Derives de benzazepine |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| NZ330973A (en) * | 1996-03-08 | 2000-03-27 | Zeneca Ltd | Azolobenzazepine derivatives as neurologically active agents |
| AU5330698A (en) * | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| IL135303A0 (en) * | 1997-09-29 | 2001-05-20 | Meiji Seika Kaisha | Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| AU1651201A (en) | 1999-12-06 | 2001-06-18 | Ajinomoto Co., Inc. | Amidinophenylpyruvic acid derivative |
| EP1345925B1 (en) | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (de) * | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
| WO2003013545A1 (en) | 2001-08-09 | 2003-02-20 | Actelion Pharmaceuticals Ltd | Novel benzo-fused heterocycles as endothelin antagonisits |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| ATE381566T1 (de) * | 2004-05-14 | 2008-01-15 | Millennium Pharm Inc | Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase |
| US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| ES2408318T3 (es) | 2005-12-23 | 2013-06-20 | Glaxosmithkline Llc | Inhibidores de azaindol de las cinasas Aurora |
| WO2008021038A2 (en) | 2006-08-09 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
-
2007
- 2007-11-09 CL CL200703244A patent/CL2007003244A1/es unknown
- 2007-11-14 EP EP07867449A patent/EP2086981B1/en active Active
- 2007-11-14 SI SI200730975T patent/SI2086981T1/sl unknown
- 2007-11-14 MX MX2009004670A patent/MX2009004670A/es active IP Right Grant
- 2007-11-14 WO PCT/US2007/023948 patent/WO2008063525A1/en not_active Ceased
- 2007-11-14 CA CA2669680A patent/CA2669680C/en active Active
- 2007-11-14 PL PL07867449T patent/PL2086981T3/pl unknown
- 2007-11-14 EP EP12153134.7A patent/EP2497773B1/en active Active
- 2007-11-14 ES ES12153134.7T patent/ES2537451T3/es active Active
- 2007-11-14 ES ES12153131.3T patent/ES2528793T3/es active Active
- 2007-11-14 NZ NZ611898A patent/NZ611898A/en not_active IP Right Cessation
- 2007-11-14 AU AU2007322046A patent/AU2007322046B2/en active Active
- 2007-11-14 PT PT121531313T patent/PT2497772E/pt unknown
- 2007-11-14 EP EP12153131.3A patent/EP2497772B1/en active Active
- 2007-11-14 PT PT07867449T patent/PT2086981E/pt unknown
- 2007-11-14 DK DK07867449.6T patent/DK2086981T3/da active
- 2007-11-14 US US11/985,277 patent/US8026246B2/en active Active
- 2007-11-14 SG SG10201503350TA patent/SG10201503350TA/en unknown
- 2007-11-14 BR BRPI0718803A patent/BRPI0718803B8/pt active IP Right Grant
- 2007-11-14 SI SI200731591T patent/SI2497772T1/sl unknown
- 2007-11-14 JP JP2009537199A patent/JP5102839B2/ja active Active
- 2007-11-14 EP EP15155821.0A patent/EP2944639B1/en active Active
- 2007-11-14 NZ NZ597252A patent/NZ597252A/xx unknown
- 2007-11-14 MY MYPI20091846A patent/MY153243A/en unknown
- 2007-11-14 RS RS20150047A patent/RS53788B1/sr unknown
- 2007-11-14 PL PL12153131T patent/PL2497772T3/pl unknown
- 2007-11-14 KR KR1020097012501A patent/KR101110458B1/ko active Active
- 2007-11-14 MX MX2012011396A patent/MX348568B/es unknown
- 2007-11-14 RS RS20120247A patent/RS52313B/sr unknown
- 2007-11-14 MX MX2012011398A patent/MX343391B/es unknown
- 2007-11-14 ZA ZA200903279A patent/ZA200903279B/xx unknown
- 2007-11-14 CN CN201310367332.9A patent/CN103483343B/zh active Active
- 2007-11-14 CN CN2007800423837A patent/CN101547924B/zh active Active
- 2007-11-14 KR KR1020117022355A patent/KR101342014B1/ko active Active
- 2007-11-14 EA EA200970486A patent/EA015779B1/ru unknown
- 2007-11-14 GE GEAP200711309A patent/GEP20125459B/en unknown
- 2007-11-14 SG SG2011080652A patent/SG176443A1/en unknown
- 2007-11-14 AT AT07867449T patent/ATE556076T1/de active
- 2007-11-14 ES ES07867449T patent/ES2384123T3/es active Active
- 2007-11-14 UA UAA200906211A patent/UA94129C2/ru unknown
- 2007-11-14 TW TW096143087A patent/TWI401255B/zh active
- 2007-11-14 NZ NZ577042A patent/NZ577042A/en unknown
- 2007-11-14 DK DK12153131.3T patent/DK2497772T3/en active
- 2007-11-14 HR HRP20120490TT patent/HRP20120490T1/hr unknown
- 2007-11-16 AR ARP070105104A patent/AR064246A1/es unknown
-
2009
- 2009-05-08 CR CR10782A patent/CR10782A/es unknown
- 2009-05-11 IL IL198690A patent/IL198690A0/en active IP Right Grant
- 2009-05-13 NO NO20091864A patent/NO343338B1/no unknown
- 2009-06-12 MA MA31985A patent/MA30988B1/fr unknown
-
2011
- 2011-08-25 US US13/217,659 patent/US20110312942A1/en not_active Abandoned
- 2011-08-25 US US13/217,729 patent/US9988384B2/en active Active
- 2011-08-30 JP JP2011187930A patent/JP5452811B2/ja active Active
-
2012
- 2012-06-06 CY CY20121100518T patent/CY1112828T1/el unknown
- 2012-10-12 PH PH12012502057A patent/PH12012502057B1/en unknown
-
2013
- 2013-11-15 JP JP2013236439A patent/JP2014055166A/ja active Pending
-
2014
- 2014-04-04 CR CR20140154A patent/CR20140154A/es unknown
- 2014-10-15 US US14/514,687 patent/US9765076B2/en active Active
- 2014-11-27 CR CR20140544A patent/CR20140544A/es unknown
-
2015
- 2015-01-13 HR HRP20150047TT patent/HRP20150047T1/hr unknown
-
2018
- 2018-06-01 US US15/996,166 patent/US10836766B2/en active Active
-
2020
- 2020-11-16 US US17/099,266 patent/US11958855B2/en active Active
-
2024
- 2024-03-07 US US18/598,629 patent/US20240400567A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7380507B2 (ja) | Ｓｔｉｎｇ作動化合物 | |
| CA2669680A1 (en) | Compounds for inhibiting mitotic progression | |
| IL295603A (en) | Protein compounds and their uses | |
| JP7681737B2 (ja) | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 | |
| JP2018533611A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2005524631A5 (enExample) | ||
| JP2009515980A5 (enExample) | ||
| EP2305642A3 (en) | Bis(thio-hydrazide amide) salts for treatment of cancers | |
| JP2006507235A5 (enExample) | ||
| JP2007517044A5 (enExample) | ||
| WO2018043747A1 (ja) | 抗ｂ型肝炎ウイルス剤 | |
| RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
| JP2007529421A5 (enExample) | ||
| JP2018501315A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2006513208A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2017514809A5 (enExample) | ||
| RU2014131065A (ru) | Димерные соединения-агонисты рецептора fgf ( fgfr ), способ их получения и их терапевтическое применение | |
| JP2013532652A5 (enExample) | ||
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2016525104A5 (enExample) |